Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 5
2005 1
2008 1
2014 1
2015 1
2019 4
2020 1
2021 7
2022 6
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria.
Kulasekararaj AG, Lehtinen AE, Forsyth C, Gandhi S, Griffin M, Körper S, Mikala G, Muus P, Overgaard U, Patriquin CJ, Pullon H, Shen YM, Spearing R, Szer J, De la Borderie G, Duda PW, Farzaneh-Far R, Ragunathan S, Sayegh CE, Vadysirisack DD, Schrezenmeier H. Kulasekararaj AG, et al. Among authors: korper s. Haematologica. 2024 Mar 1;109(3):929-935. doi: 10.3324/haematol.2022.281780. Haematologica. 2024. PMID: 37534517 Free PMC article. Clinical Trial. No abstract available.
SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays.
Seidel A, Hoffmann S, Jahrsdörfer B, Körper S, Ludwig C, Vieweg C, Albers D, von Maltitz P, Müller R, Lotfi R, Wuchter P, Klüter H, Kirchhoff F, Schmidt M, Münch J, Schrezenmeier H. Seidel A, et al. Among authors: korper s. Front Immunol. 2023 Apr 25;14:1170759. doi: 10.3389/fimmu.2023.1170759. eCollection 2023. Front Immunol. 2023. PMID: 37180152 Free PMC article.
Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial.
Desmarets M, Hoffmann S, Vauchy C, Rijnders BJA, Toussirot E, Durrbach A, Körper S, Schrezenmeier E, van der Schoot CE, Harvala H, Brunotte G, Appl T, Seifried E, Tiberghien P, Bradshaw D, Roberts DJ, Estcourt LJ, Schrezenmeier H. Desmarets M, et al. Among authors: korper s. BMJ Open. 2023 Apr 27;13(4):e071277. doi: 10.1136/bmjopen-2022-071277. BMJ Open. 2023. PMID: 37105693 Free PMC article.
New Trends in Hemapheresis.
Worel N, Buser A, Körper S. Worel N, et al. Among authors: korper s. Transfus Med Hemother. 2023 Mar 2;50(2):75. doi: 10.1159/000529738. eCollection 2023 Apr. Transfus Med Hemother. 2023. PMID: 37066052 Free PMC article. No abstract available.
[Value of convalescent plasma in the therapy of COVID-19].
Körper S, Seifried E, Schrezenmeier H. Körper S, et al. Dtsch Med Wochenschr. 2023 Mar;148(7):423-426. doi: 10.1055/a-2013-8775. Epub 2023 Mar 20. Dtsch Med Wochenschr. 2023. PMID: 36940693 German.
Fatal Puumala Hantavirus Infection in a Patient with Common Variable Immunodeficiency (CVID).
Steininger P, Herbst L, Bihlmaier K, Willam C, Körper S, Schrezenmeier H, Klüter H, Pfister F, Amann K, Weiss S, Krüger DH, Zimmermann R, Korn K, Hofmann J, Harrer T. Steininger P, et al. Among authors: korper s. Microorganisms. 2023 Jan 21;11(2):283. doi: 10.3390/microorganisms11020283. Microorganisms. 2023. PMID: 36838248 Free PMC article.
Immune Plasma for the Treatment of COVID-19: Lessons Learned so far.
Schrezenmeier H, Hoffmann S, Hofmann H, Appl T, Jahrsdörfer B, Seifried E, Körper S. Schrezenmeier H, et al. Among authors: korper s. Hamostaseologie. 2023 Feb;43(1):67-74. doi: 10.1055/a-1987-3682. Epub 2023 Feb 20. Hamostaseologie. 2023. PMID: 36807822 Free article. Review.
Differentially induced immunity in buccal and nasal mucosae after vaccination for SARS-CoV-2: Prospects for mass scale immunity-screening in large populations.
Tsamadou C, Ludwig C, Scholz J, Proffen M, Hägele J, Rode I, Körper S, Fabricius D, Jahrsdörfer B, Neuchel C, Amann E, Schrezenmeier H, Fürst D. Tsamadou C, et al. Among authors: korper s. Front Immunol. 2022 Nov 17;13:999693. doi: 10.3389/fimmu.2022.999693. eCollection 2022. Front Immunol. 2022. PMID: 36466833 Free PMC article.
One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients.
Körper S, Grüner B, Zickler D, Wiesmann T, Wuchter P, Blasczyk R, Zacharowski K, Spieth P, Tonn T, Rosenberger P, Paul G, Pilch J, Schwäble J, Bakchoul T, Thiele T, Knörlein J, Dollinger MM, Krebs J, Bentz M, Corman VM, Kilalic D, Schmidtke-Schrezenmeier G, Lepper PM, Ernst L, Wulf H, Ulrich A, Weiss M, Kruse JM, Burkhardt T, Müller R, Klüter H, Schmidt M, Jahrsdörfer B, Lotfi R, Rojewski M, Appl T, Mayer B, Schnecko P, Seifried E, Schrezenmeier H. Körper S, et al. J Clin Invest. 2022 Dec 15;132(24):e163657. doi: 10.1172/JCI163657. J Clin Invest. 2022. PMID: 36326824 Free PMC article. Clinical Trial.
Cytokine levels associated with favorable clinical outcome in the CAPSID randomized trial of convalescent plasma in patients with severe COVID-19.
Körper S, Schrezenmeier EV, Rincon-Arevalo H, Grüner B, Zickler D, Weiss M, Wiesmann T, Zacharowski K, Kalbhenn J, Bentz M, Dollinger MM, Paul G, Lepper PM, Ernst L, Wulf H, Zinn S, Appl T, Jahrsdörfer B, Rojewski M, Lotfi R, Dörner T, Jungwirth B, Seifried E, Fürst D, Schrezenmeier H. Körper S, et al. Front Immunol. 2022 Oct 6;13:1008438. doi: 10.3389/fimmu.2022.1008438. eCollection 2022. Front Immunol. 2022. PMID: 36275695 Free PMC article. Clinical Trial.
34 results